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ABSTRACT
Introduction: A cost-effectiveness analysis was
conducted comparing a fixed-ratio combination
(FRC) of insulin glargine 100 units/mL plus
lixisenatide (iGlarLixi) versus the FRC of insulin
degludec plus liraglutide (iDegLira) and the free-
combination comparators insulin glargine plus
dulaglutide (iGlar plus Dula) and basal insulin
plus liraglutide (BI plus Lira).
Methods: The IQVIA Core Diabetes Model was
used to estimate lifetime costs and outcomes for
a cohort of patients with type 2 diabetes melli-
tus (T2DM) from the UK healthcare perspective.
Initial clinical data for iGlarLixi were based on
the randomized, controlled LixiLan-L trial and
the relative treatment effects for comparators
were based on an indirect treatment compar-
ison using data from the AWARD-9 (iGlar plus
Dula), LIRA ADD2 BASAL (BI plus Lira), and
DUAL V (iDegLira) trials. Costs were derived
from publicly available sources. Lifetime costs
(in British Pound Sterling [£]) and quality-ad-
justed life-years (QALYs) were predicted; net
monetary benefit (NMB) for iGlarLixi versus
comparators was derived using a willingness-to-
pay threshold of £20,000. Extensive scenario
and sensitivity analyses were conducted.
Results: Estimated costs were lowest with
iGlarLixi (£31,295) compared with iGlar plus
Dula (£38,790), iDegLira (£40,179), and BI plus
Lira (£42,467). Total QALYs gained were iden-
tical with iGlarLixi and iDegLira (8.438), and
comparable with iGlar plus Dula (8.439) and BI
plus Lira (8.466). NMB for iGlarLixi was positive
versus all comparators (£10,603.86 vs. BI plus
Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs.
iDegLira).
Conclusion: In patients with T2DM with sub-
optimal glycemic control on basal insulin,
iGlarLixi provides very similar outcomes and
substantial cost savings, compared with other
fixed and free combinations of insulins plus
glucagon-like peptide-1 receptor agonists.
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Key Summary Points
Why carry out this study?
Patients with type 2 diabetes mellitus
(T2DM) who do not achieve target levels
of glycated hemoglobin (HbA1c) despite
escalating therapy and treatment with
basal insulin (BI) analogs require further
intensification of the insulin regimen to
achieve glycemic control.
The combination of injectable glucagon-
like peptide-1 receptor agonists (GLP-1
RA) and BI therapy has been shown to
improve glycemic control compared with
insulin alone, but separate injectables are
associated with increased regimen
complexity, additional costs, and poorer
adherence.
As no economic evaluation of the
available fixed-ratio combination (FRC)
and free-combination regimens of BI plus
GLP-1 RA has been undertaken to date, a
comparative cost-effectiveness
comparison of the FRCs insulin analog
glargine plus lixisenatide (iGlarLixi) and
insulin degludec plus liraglutide
(iDegLira) with the free-combination
comparators insulin glargine plus
dulaglutide (iGlar plus Dula) and basal
insulin plus liraglutide (BI plus Lira) was
conducted.
What was learned from this study?
iGlarLixi was less costly (iGlarLixi:
£31,295, iGlar plus Dula: £38,790,
iDegLira: £40,179, BI plus Lira: £42,467)
and total quality-adjusted life-years
gained were identical with iGlarLixi and
iDegLira (8.438), and comparable with
iGlar plus Dula (8.439) and BI plus Lira
(8.466).
In patients with T2DM with suboptimal
glycemic control on basal insulin,
iGlarLixi provides comparable outcomes
and substantial cost savings, compared
with other fixed and free combinations of
BI plus GLP-1 RA, and was considered to
be cost-effective over a lifetime time
horizon.
INTRODUCTION
Diabetes remains one of the most impactful
global health threats, and clinical management
of people with type 2 diabetes mellitus (T2DM)
represents a major public health challenge and
a pressing economic burden for payers in the
UK. Subsequent to lifestyle interventions and
iterative dose escalation with oral antidiabetic
drugs (OADs), some patients with T2DM do not
achieve their individually recommended target
levels of glycated hemoglobin (HbA1c) and may
further escalate therapy and receive basal insu-
lin (BI) analogs, in line with guidance from the
American Diabetes Association, European Asso-
ciation for the Study of Diabetes, and National
Institute for Health and Care Excellence (NICE)
[1, 2]. However, despite the proven efficacy of BI
regimens in clinical studies [3], a substantial
proportion of patients with T2DM continue to
experience suboptimal glycemic control with BI
analog monotherapy, and further intensifica-
tion of the insulin regimen is often required to
achieve glycemic control [4, 5].
The development of injectable glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) offers a
complementary mechanism of action to BI
analogs through their action to reduce post-
prandial glucose excursions by enhancing glu-
cose-stimulated insulin secretion and delaying
gastric emptying. In addition, GLP-1 RAs reduce
appetite [6], thereby improving glycemic con-
trol while minimizing the side effects of hypo-
glycemia and weight gain. The combination of
GLP-1 RA and BI therapy has been shown to
improve glycemic control compared with insu-
lin alone [7–9]. However, combining both of
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these agents as separate injectables is associated
with increased regimen complexity and addi-
tional costs [10], and may be associated with
poorer adherence [11]. The combination of BI
with GLP-1 RAs administered as a single fixed-
ratio combination (FRC) injection offers addi-
tional convenience, which facilitates dual
treatment initiation, simplification of the dos-
ing schedule, and easy titration for physicians
and patients [12, 13].
Two FRCs of insulin plus GLP-1 RA are cur-
rently approved for use in the EU. The FRC
iDegLira, comprising insulin degludec and the
GLP-1 RA liraglutide, is approved in the EU for
use in adults with insufficiently controlled
T2DM as an adjunct to diet and exercise, in
addition to other OADs [14]. In the DUAL V
clinical trial, which assessed patients with
T2DM with inadequate glycemic control during
therapy with insulin glargine plus metformin,
those who received iDegLira had a significantly
improved HbA1c reduction, hypoglycemic
event rate, and body weight outcomes com-
pared with insulin glargine [15]. The FRC
iGlarLixi (Suliqua; Sanofi, Paris, France) com-
prises the long-acting insulin analog glargine
100 units/mL and the GLP-1 RA lixisenatide,
and is approved in the EU for use in adults with
insufficiently controlled T2DM as an adjunct to
diet and exercise, in addition to metformin,
with or without sodium-glucose co-transporter-
2 inhibitors [16]. The LixiLan-L clinical trial
(ClinicalTrials.gov: NCT02058160) demon-
strated that in patients with T2DM who had
suboptimal glycemic control despite BI therapy
(with or without metformin), iGlarLixi was
associated with a significant reduction in HbA1c
and significantly more patients achieving target
HbA1c\ 7.0% compared with insulin glargine
alone (55 vs. 30% of patients; P\ 0.0001), and
was not associated with an increased risk of
hypoglycemia [17].
A comprehensive economic analysis com-
paring available BI plus GLP-1 RA FRCs and free-
combination regimens of BI plus GLP-1 RA in
patients with T2DM suboptimally controlled
with BI has not previously been conducted. We
therefore conducted a cost-effectiveness com-
parison of the FRCs iGlarLixi and iDegLira with
the free-combination comparators insulin
glargine plus dulaglutide 1.5 mg (iGlar plus




The IQVIA Core Diabetes Model (CDM) is a
non-product-specific cohort simulation model
that determines long-term health outcomes and
cost consequences of interventions in type 1
and type 2 diabetes mellitus [18, 19]. The CDM
is designed to take surrogate endpoints (HbA1c,
blood pressure, lipids, weight, hypoglycemia)
and translate them into long-term health eco-
nomic outcomes (life expectancy, micro- and
macrovascular complications, quality-adjusted
life expectancy, total costs). The clinical setting
for this model was patients with T2DM with
suboptimal glycemic control on a BI analog
(with or without C 2 OADs) who were consid-
ered appropriate for treatment intensification
with a GLP-1 RA. The baseline patient charac-
teristics were sourced from the LixiLan-L trial
[17]. Outcomes over a lifetime time horizon
were estimated using version 9.5 of the IQVIA
CDM; model structure and analysis is described
in further detail in the complementary article
also published in this issue [20].
This cost-effectiveness analysis was con-
ducted in line with NICE guidance and from the
perspective of the UK National Health Service,
using a hypothetical cohort of 1000 patients, a
lifetime time horizon, and an annual discount
rate of 3.5% for both costs and outcomes [21].
Model Inputs and Structure
Baseline characteristics were based primarily on
those reported in the LixiLan-L clinical trial
[17]; baseline HbA1c was 8.08%. For laboratory
parameters, waist circumference, waist-to-hip
ratio, and proportion of patients with severe
vision loss, default values in the CDM were used
(Table 1). The treatment effect of iGlarLixi on
HbA1c in the first year of the model was based
on the outcomes observed in the LixiLan-L trial
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Table 1 Baseline characteristics
Variable Mean (SD) References
Patient demographics
Start age 60.00 years (9.1) [17]
Duration of diabetes 12.00 years (6.74) [17]
Proportion male 0.467 [17]
Baseline risk factors
HbA1c 8.08% (0.71) [17]
Systolic blood pressure 131.86 mmHg (14.20) LixiLan-L study report
Diastolic blood pressure 80.95 mmHg (0) CDM default
Total cholesterol 180.52 mg/dL (44.76) LixiLan-L study report
High-density lipoprotein 50.62 mg/dL (13.18) LixiLan-L study report
Low-density lipoprotein 100.55 mg/dL (37.79) LixiLan-L study report
Triglycerides 149.13 mg/dL (98.39) LixiLan-L study report
Body mass index 31.14 kg/m2 (4.20) [17]
Estimated glomerular filtration rate 77.50 mL/min/1.73 m2 (0) CDM default
Hemoglobin 14.50 g/dL (0) CDM default
White blood cells 6.80 106/mL (0) CDM default
Heart rate 72.00 bpm (0) CDM default
Waist-to-hip ratio 0.93 CDM default
Urinary albumin to creatinine ratio 3.10 mg/mmol CDM default
Serum creatinine 1.10 mg/dL (0) CDM default
Serum albumin 3.90 g/dL CDM default
Waist circumference 87.84 cm CDM default
Proportion smoker 0.17 [39]
Cigarettes/day 12.00 [39]
Alcohol consumption 6.80 oz/week [40]
Racial characteristics
Proportion White 0.756 [17]
Proportion Black 0.052 [17]
Proportion Hispanic 0.165 [17]
Proportion Native American 0.006 [17]
Proportion Asian/Pacific Islander 0.021 [17]
Baseline CVD complications
Proportion myocardial infarction 0.058 LixiLan-L study report
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[17] (Table 2); an indirect treatment comparison
(ITC) using Bucher methodology was conducted
to provide an estimate of relative treatment
effects on HbA1c for iGlar plus Dula, BI plus
Lira, and iDegLira [22]. Data from the following
phase 3 trials in patients with suboptimal gly-
cemic control with BI were used to conduct the
ITC: the AWARD-9 study (NCT02152371),
assessing iGlar plus Dula [23]; the LIRA ADD2
BASAL study (NCT02964247), assessing BI plus
Lira [24]; and the DUAL V study
(NCT01952145), assessing iDegLira [15]
(Table 2). After the first year of treatment, the
progression of HbA1c was predicted based on
the UK Prospective Diabetes Study (UKPDS) 68
risk equation [25]; for cardiovascular diseases
and mortality, the UKPDS 82 risk equations
were used [26]. As the effect on body mass index
Table 1 continued
Variable Mean (SD) References
Proportion angina 0.108 LixiLan-L study report
Proportion peripheral vascular disease 0.055 LixiLan-L study report
Proportion stroke 0.027 LixiLan-L study report
Proportion heart failure 0.058 LixiLan-L study report
Proportion atrial fibrillation 0.037 LixiLan-L study report
Proportion left ventricular hypertrophy 0.004 LixiLan-L study report
Baseline renal complications
Proportion microalbuminuria 0.085 LixiLan-L study report
Proportion macroalbuminuria 0.020 LixiLan-L study report
Proportion end-stage renal disease 0.000 LixiLan-L study report
Baseline retinopathy complications
Proportion background diabetic retinopathy 0.042 LixiLan-L study report
Proportion proliferative diabetic retinopathy 0.015 [41]
Proportion severe vision loss 0.002 LixiLan-L study report
Baseline macular edema
Proportion macular edema 0.000 CDM default
Baseline cataract
Proportion cataract 0.113 LixiLan-L study report
Baseline foot ulcer complications
Proportion ulcer 0.011 LixiLan-L study report
Proportion history of amputation 0.000 LixiLan-L study report
Baseline neuropathy
Proportion neuropathy 0.382 LixiLan-L study report
Proportion depression 0.064 LixiLan-L study report
bpm Beats per minute, CDM Core Diabetes Model, CVD cardiovascular disease, HbA1c glycated hemoglobin, SD standard
deviation
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(BMI) was not reported in primary publications
for relevant trials, it was assumed that there was
no difference to the effect on BMI between
interventions in the base case; this assumption
was tested in sensitivity analyses. All therapies
were assumed to be followed by a rescue therapy
(addition of a rapid-acting insulin) after patients
exceeded a threshold of HbA1c 8.08% (i.e. their
HbA1c has returned to baseline levels). The
estimated reduction in HbA1c following the
addition of rescue therapy was approximated
based on the GetGoal Duo-2 trial [27], in which
the addition of bolus insulin to BI reduced
HbA1c by 0.6%. Formal comparisons of hypo-
glycemia were limited by between-study differ-
ences in the definitions of hypoglycemia.
For the derivation of quality-adjusted life-
years (QALYs), an additive ‘‘core default
method’’ approach was used: for patients with
multiple comorbidities (e.g. history of stroke
and myocardial infarction [MI]), the lowest
utility value was assigned, and event disutilities
were then added for events that occur in that
year, resulting in an annual utility score for
each simulated patient [19]. Utility and disutil-
ity weightings were taken from previously
published cost-effectiveness evaluations using
the CDM [28] (see Electronic Supplementary
Material [ESM] Table S1).
Cost Data
Direct medical costs, comprising drug costs,
administration costs, glucose monitoring costs,
and costs of T2DM complications (cardiovas-
cular, renal, acute events, eye disease, neu-
ropathy, foot ulcer, and amputation), were
calculated for each year of therapy, based on
published literature and UK national sources
(Table 3). Treatment costs for insulins were
calculated based on the daily doses reported by
source trials. The cost of insulin glargine was
conservatively assumed to equal the cost of the
biosimilar insulin glargine, Semglee (Biocon
Biologics Ltd., Bengaluru, India). In the EU,
iGlarLixi is available as two FRCs: 100 units/mL
insulin glargine plus 50 l/mL lixisenatide
(Suliqua SoloStar pen 10–40 units, hereinafter
‘‘iGlarLixi 100/50’’) and 100 units/mL insulin
glargine plus 33 l/mL lixisenatide (Suliqua
SoloStar pen 30–60 units, hereinafter ‘‘iGlarLixi
100/33’’). The cost of iGlarLixi in the first year
was estimated based on assumed use of the
iGlarLixi 100/50 FRC for 3 months followed by
use of iGlarLixi 100/33 FRC for the remaining
9 months of that first year. From the second
year onward, it was assumed that only the
iGlarLixi 100/33 formulation was used. This is a
conservative approach considering the titration
period and final dose of 46.7 IU reached at the
end of the treatment period in the LixiLan-L
trial.
All patients were assumed to also be receiv-
ing concurrent metformin as oral diabetes
therapy. Following treatment switch to rescue
therapy (addition of a rapid-acting insulin, after
patients’ HbA1c returned to baseline levels of
8.08%), costs resulting from the addition of
rapid-acting insulin were added. All costs were
reported in 2020 British Pound Sterling (GBP
[£]) and, if necessary, inflated to 2020 costs
using the Hospital and Community Health
Service Index from the Personal Social Services
Research Unit [29]. Latest official tariffs were
used where applicable.
Table 2 Treatment effects used in the base case analysis
Treatment effect iGlarLixia BI plus Lirab iGlar plus Dulab iDegLirab
LSM change in HbA1c from baseline, % (SD) - 1.13 (0.06) - 1.83 (0.14) - 1.40 (0.16) - 1.31 (0.13)
BI basal insulin, Dula Dulaglutide, HbA1c glycated hemoglobin, iDegLira insulin degludec plus liraglutide, iGlar insulin
glargine, iGlarLixi insulin glargine 100 units/mL plus lixisenatide, Lira liraglutide, LSM least squares mean
aBased on results of the LixiLan-L trial [17]
bDerived from Bucher indirect treatment comparison of phase 3 trials: AWARD-9 [23], LIRA ADD2 BASAL [24], and
DUAL V [15]
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Analyses
Incremental differences in costs and QALYs
were obtained for iGlarLixi versus BI plus Lira,
iGlar plus Dula, and iDegLira; incremental cost-
effectiveness ratio (ICER) estimates were calcu-
lated for iGlarLixi relative to each comparator.
Additionally, cost impact was assessed using the
net monetary benefit (NMB) approach, conser-
vatively based on the lower range (£20,000) of
the commonly accepted UK willingness-to-pay
(WTP) threshold of £20,000–30,000 [21]. Posi-
tive NMB values indicate that an intervention is
cost-effective compared with the alternative at a
given WTP threshold [30].
Scenario analyses were performed on key
parameters to assess the robustness of the base
case findings (ESM Table S2). A probabilistic
sensitivity analysis (PSA), including 1000 model
iterations in which key parameter inputs were
altered within plausible distribution estimates,
was also conducted to capture uncertainty and
assess the imprecision of the results. Proba-
bilistic distribution of key transition probabili-
ties (for MI, stroke, congestive heart failure, and
angina) were applied by bootstrap sampling
around the 95% confidence interval of the
regression coefficient. For utilities and treat-
ment effects, mean and standard error values
were used to generate random sampling within
a beta-distribution function. Direct costs (ex-
cluding acquisition costs, which were assumed
to be fixed) were randomly sampled based on
log-normal distribution within a 10% variance.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
Table 3 Annual treatment costs in first line and rescue therapy line
Annual treatment costs (£)a iGlarLixi BI plus Lira iDegLira iGlar plus Dula
First-line therapy
Acquisition cost (1st year) 1010.64 1774.34 1589.54 1487.65
Acquisition cost (C 2nd year)b 921.09 1774.34 1589.54 1487.65
Metformin add-on 17.19 17.19 17.19 17.19
Administration costs (needles) 28.86 28.86 28.86 28.86
Self-glucose monitoring 128.86 128.98 128.98 128.98
Annual cost (1st year) 1185.66 1949.37 1764.56 1662.68
Annual cost (C 2nd year) 1096.11 1949.37 1764.56 1662.68
Rescue therapy
Rapid-acting insulin 70.04 70.04 70.04 70.04
Additional needle use 57.71 57.71 57.71 57.71
First-line treatment 1096.11 1949.37 1764.56 1662.68
Annual cost 1223.87 2077.12 1892.32 1790.43
All drug costs were sourced from the British National Formulary [42]
Posology was based on the LixiLan-L trial [17] for iGlarLixi, the LIRA ADD2 BASAL trial [24] for BI plus Lira, the British
National Formulary for BI plus Lira [23], and the DUAL V trial [15] for iDegLira
BI basal insulin, Dula Dulaglutide, iDegLira insulin degludec plus liraglutide, iGlar insulin glargine, iGlarLixi insulin
glargine 100 units/mL plus lixisenatide, Lira liraglutide
aAll costs are given in British Pound Sterling (£)
bAll patients receiving iGlarLixi were assumed to be receiving the iGlarLixi 100/33 ratio formulation from year 2 onward
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RESULTS
Base Case Analysis
Total QALYs gained were identical with iGlar-
Lixi and iDegLira (8.438), and almost identical
with iGlar plus Dula (8.439) and BI plus Lira
(8.466) (Table 4). Estimated total costs were
lowest with iGlarLixi (£31,295), compared with
iGlar plus Dula (£38,790), iDegLira (£40,179),
and BI plus Lira (£42,467). Treatment switching
to rescue therapy occurred after year 5 with
iGlarLixi, iGlar plus Dula, and iDegLira, and
after year 6 with BI plus Lira; predicted HbA1c
levels with each comparator converged over
time. Estimated event rates for key diabetes-
related complications were comparable between
comparators (ESM Fig. S1). Owing to difficulties
when interpreting ICERs in the south-west
quadrant (Fig. 1), NMB was estimated at a WTP
threshold of £20,000. For all comparisons, the
NMB of iGlarLixi was positive; the NMB of
iGlarLixi was £10,603.86 versus BI plus Lira,
£7,466.24 versus iGlar plus Dula, and £8874.11
versus iDegLira (Table 4).
The key driver for cost savings with iGlarLixi
was the estimated annual acquisition costs
(£1011 in the first year, £921 in subsequent
years) compared with BI plus Lira (£1774
annually), iGlar plus Dula (£1488 annually),
and iDegLira (£1590 annually). Costs associated
with management and complications were
similar between comparators.
Scenario Analyses
Multiple scenario and one-way analyses were
conducted to assess the robustness of the base
case model assumptions (ESM Table S3). Base
case results remained robust to parameter and
assumption variation in all scenario analyses.
The NMB for iGlarLixi ranged from £2818 to
£16,163 versus BI plus Lira; from £2296 to
£11,311 versus iGlar plus Dula; and from £2775
to £13,470 versus iDegLira.
Probabilistic Sensitivity Analysis
For iGlarLixi versus each comparator, all itera-
tions of the PSA demonstrated cost savings for
iGlarLixi, but a substantial proportion of itera-
tions resulted in fewer QALYs gained for iGlar-
Lixi (ranging from 52% of iterations vs.
iDegLira, to 60% of iterations vs. BI plus Lira;
Fig. 1). Nevertheless, at a WTP threshold of
£20,000/QALY, iGlarLixi was cost-effective in
approximately 98% of iterations in each com-
parison (Fig. 1b).
Table 4 Cost-effectiveness results (base case analysis)
Cost-effectiveness variables iGlarLixi BI plus Lira iGlar plus Dula iDegLira
QALY, year 8.438 8.466 8.439 8.438
Total cost, £ 31,295 42,467 38,790 40,179
Incremental QALY, year – - 0.028 - 0.001 - 0.001
Incremental costs, £ – - 11,171 - 7494.97 - 8884.11
ICER, £ per QALY gained – 393,366 5353,551 17,768,220
NMB, £ – 10,603.86 7466.24 8874.11
BI basal insulin, Dula Dulaglutide, iDegLira insulin degludec plus liraglutide, iGlar insulin glargine, iGlarLixi insulin
glargine 100 units/mL plus lixisenatide, ICER Incremental cost-effectiveness ratio, Lira liraglutide, NMB net monetary
benefit, QALY quality-adjusted life-year
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Fig. 1 Base case cost-effectiveness planes and cost-effectiveness acceptability curves for iGlarLixi versus: a, b BI plus Lira, c,
d iGlar plus Dula, e, f iDegLira. BI basal insulin, Dula dulaglutide, ICER incremental cost-effectiveness ratio, iDegLira
insulin degludec plus liraglutide, iGlar insulin glargine, iGlarLixi insulin glargine 100 units/mL plus lixisenatide, Lira
liraglutide, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-years, WTP willingness to pay
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DISCUSSION
This study evaluated the cost-effectiveness of
iGlarLixi and demonstrated that iGlarLixi pro-
vides comparable efficacy with iDegLira, BI plus
Lira, and iGlar plus Dula, but is less costly than
these comparators, and is therefore likely to
represent a cost-effective alternative for health-
care payers. Extensive scenario analyses and PSA
consistently supported the base case findings,
demonstrating the robustness of these outcomes.
Previous publications have reported on cost-
effectiveness estimates for iDegLira versus
iGlarLixi from Italian and Czech Republic per-
spectives. In the Italian estimate, iDegLira was
associated with an incremental cost of €930 and
a gain of 0.13 QALYs [31], while in the Czech
Republic the incremental cost was estimated to
be CZK 94,029 (£3164) for the iGlarLixi 100/33
(30–60) pen and CZK 47,058 (£1583) for the
iGlarLixi 100/50 (10–40) pen, with a gain of 0.14
QALYs [32]. These cost estimates are qualita-
tively different from those presented in this UK
analysis, which consistently demonstrated
iGlarLixi to be less expensive than comparators,
but in both analyses, the ICER estimates for
iDegLira were well below local WTP thresholds.
However, both analyses relied on the same
indirect comparison, taking the treatment effect
from the DUAL II trial for iDegLira; patient
characteristics in DUAL V are closer to those in
LixiLan-L [33]. Furthermore, these analyses
assumed that the treatment effect in HbA1c and
BMI was maintained over 5 years, while in our
analysis we assumed that after the first year, the
progression of HbA1c was predicted with the
UKPDS 68 equation. Upon treatment intensifi-
cation after 5 years, HbA1c 7% was assumed for
the remainder of patients’ lifetimes. Our analysis
assumed patients were switched to rescue ther-
apy once they reached their HbA1c baseline
value again, and HbA1c reduction of 0.6% was
applied to rescue therapy for the first year with
the progression of HbA1c predicted from UKPDS
68 for the remainder of patients’ lifetimes. For
utility values, we applied the lowest-state utility
associated with existing comorbidities.
QALY outcomes were very similar with each
comparator in this analysis. NMB can more
accurately capture cost benefits when the ICER
lies in the south-west quadrant of the effective-
ness plane and incremental differences are mar-
ginal. NMB is being used increasingly in health
economic evaluation; indeed, it was recently
used by NICE to rank BI therapies in the eco-
nomic report underpinning their guidance for
diagnosis and management of type 1 diabetes
[34]. In our analysis, the base case and all sce-
nario analyses had positive NMB estimates,
indicating that the cost savings with iGlarLixi
outweighed the value of the marginal (and likely
clinically non-meaningful) differences in QALYs.
There are several limitations with this
approach. The model relies on short-term (26–-
30 weeks) data from two trials to extrapolate
long-term projections; however, only long-term
analyses are suitable to capture the full economic
and clinical impact of chronic conditions, as
recommended by the American Diabetes Asso-
ciation [35]. Similarly, the model outcomes
assume consistent and reliable treatment effects
over time; such observations have been difficult
to obtain in real-world clinical practice owing to
issues with adherence and persistence to therapy
[36–38], but this limitation is likely to apply
equally to all comparators. A further limitation
for this analysis is the lack of direct head-to-head
trial data to inform the model. In the absence of
such data, relative efficacy values for compara-
tors were derived from an ITC. The base case
considered only the relative HbA1c treatment
effect while the BMI effect was assumed to be
equal between comparators, and hypoglycemia
rates were predicted with risk equations owing to
inconsistent definitions used in studies. As BMI
and hypoglycemia are core components of the
progression of diabetes complications over time,
and are an important measure of the impact of
treatment on patients, these parameters were
tested in sensitivity analyses. The overall con-
clusion remained unchanged. Additionally, the
GetGoal Duo-2 trial served as proxy to estimate
the efficacy of the rescue therapy. It is likely that
this assumption underestimated treatment effi-
cacy. It should further be noted that this assess-
ment was based on the current costs of the
therapies and would therefore be subject to
change if the pricing structure for the investi-
gated therapies changes.
3226 Diabetes Ther (2021) 12:3217–3230
CONCLUSION
In conclusion, with a positive NMB in an
increasingly economically constrained envi-
ronment, these analyses show that iGlarLixi
represents good value for money to payers while
remaining a relevant therapeutic choice for
clinicians and their patients.
ACKNOWLEDGEMENTS
Funding. This study was sponsored by
Sanofi. All publication costs, including the
journal’s Rapid Service fee, were funded by
Sanofi.
Medical Writing and Editorial Assis-
tance. Medical writing support was provided by
Martin Bell and Vanessa Gross of Curo (part of
Envision Pharma Group) and was funded by
Sanofi.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Author Contributions. All authors were
responsible for the conception, study design,
and to the acquisition, analysis and interpreta-
tion of data. All authors contributed substan-
tially to drafting and revising of the manuscript.
All authors have reviewed and approved the
final version of the manuscript for submission
to Diabetes Therapy, and agree to be account-
able for its contents.
Disclosures. Rory J. McCrimmon is a mem-
ber of the advisory panel for Sanofi and Novo
Nordisk, a board member for NHS Tayside
Health Board, an employee at University of
Dundee, and has received research support from
the Medical Research Council, Wellcome, EU
Horizon 2020, JDRF, Diabetes UK, and Novo
Nordisk. Edel Falla and Jo Zhou Sha are
employees of IQVIA, which received consulting
fees for adapting the IQVIA Core Diabetes
Model to allow the analyses reported in this
manuscript. Abdul Jabbar Omar Alsaleh has
received independent contractor funding from
Sanofi for this analysis. Elisheva Lew, Richard
Hudson, and Karen Palmer are employees and
stockholders of Sanofi. Mike Baxter was an
employee and stockholder of Sanofi at the time
of the study.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any new studies with
human participants or animals performed by
any of the authors.
Data Availability. The datasets generated
during and/or analyzed during the current
study are available from the corresponding
author on reasonable request.
Open Access. This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit
line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the




1. Blonde L, Meneghini L, Peng XV, et al. Probability
of achieving glycemic control with basal insulin in
patients with type 2 diabetes in real-world practice
in the USA. Diabetes Ther. 2018;9(3):1347–58.
Diabetes Ther (2021) 12:3217–3230 3227
2. Peng XV, McCrimmon RJ, Shepherd L, et al. Gly-
cemic control following GLP-1 RA or basal insulin
initiation in real-world practice: a retrospective,
observational, longitudinal cohort study. Diabetes
Ther. 2020;11(11):2629–45.
3. Weng J, Li Y, Xu W, et al. Effect of intensive insulin
therapy on beta-cell function and glycaemic con-
trol in patients with newly diagnosed type 2 dia-
betes: a multicentre randomised parallel-group
trial. Lancet. 2008;371(9626):1753–60.
4. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to:
management of hyperglycemia in type 2 diabetes,
2018. A Consensus Report by the American Dia-
betes Association (ADA) and the European Associ-
ation for the Study of Diabetes (EASD). Diabetes
Care. 2020;43(2):487–93.
5. Davies MJ, D’Alessio DA, Fradkin J, et al. Manage-
ment of hyperglycemia in type 2 diabetes, 2018.
A Consensus Report by the American Diabetes
Association (ADA) and the European Association
for the Study of Diabetes (EASD). Diabetes Care.
2018;41(12):2669–701.
6. Meier JJ. GLP-1 receptor agonists for individualized
treatment of type 2 diabetes mellitus. Nat Rev
Endocrinol. 2012;8(12):728–42.
7. Aroda VR. A review of GLP-1 receptor agonists:
evolution and advancement, through the lens of
randomised controlled trials. Diabetes Obes Metab.
2018;20(Suppl 1):22–33.
8. Riddle MC, Aronson R, Home P, et al. Adding once-
daily lixisenatide for type 2 diabetes inadequately
controlled by established basal insulin: a 24-week,
randomized, placebo-controlled comparison (Get-
Goal-L). Diabetes Care. 2013;36(9):2489–96.
9. Maiorino MI, Chiodini P, Bellastella G, Capuano A,
Esposito K, Giugliano D. Insulin and glucagon-like
peptide 1 receptor agonist combination therapy in
type 2 diabetes: a systematic review and meta-
analysis of randomized controlled trials. Diabetes
Care. 2017;40(4):614–24.
10. Tran E. Fixed-ratio combinations. Clin Diabetes.
2017;35(4):242–6.
11. Lokhandwala T, Smith N, Sternhufvud C, Sorstadius
E, Lee WC, Mukherjee J. A retrospective study of
persistence, adherence, and health economic out-
comes of fixed-dose combination vs. loose-dose
combination of oral anti-diabetes drugs. J Med
Econ. 2016;19(3):203–12.
12. Rosenstock J, Aronson R, Grunberger G, et al. Ben-
efits of LixiLan, a titratable fixed-ratio combination
of insulin glargine plus lixisenatide, versus insulin
glargine and Lixisenatide Monocomponents in type
2 diabetes inadequately controlled on oral agents:
the LixiLan-O randomized trial. Diabetes Care.
2016;39(11):2026–35.
13. Gough SC, Bode BW, Woo VC, et al. One-year
efficacy and safety of a fixed combination of insulin
degludec and liraglutide in patients with type 2
diabetes: results of a 26-week extension to a
26-week main trial. Diabetes Obes Metab.
2015;17(10):965–73.
14. European Medicines Agency. Xultophy summary of
product characteristics. 2014. https://www.ema.
europa.eu/en/documents/product-information/
xultophy-epar-product-information_en.pdf. Acces-
sed 8 Apr 2021.
15. Lingvay I, Perez Manghi F, Garcia-Hernandez P,
et al. Effect of insulin glargine up-titration vs insu-
lin Degludec/Liraglutide on glycated hemoglobin
levels in patients with uncontrolled type 2 diabetes:
the DUAL V randomized clinical trial. JAMA.
2016;315(9):898–907.
16. European Medicines Agency. Suliqua summary of




17. Aroda VR, Rosenstock J, Wysham C, et al. Efficacy
and safety of LixiLan, a titratable fixed-ratio com-
bination of insulin glargine plus Lixisenatide in
type 2 diabetes inadequately controlled on basal
insulin and metformin: the LixiLan-L randomized
trial. Diabetes Care. 2016;39(11):1972–80.
18. Palmer AJ, Roze S, Valentine WJ, et al. The CORE
diabetes model: projecting long-term clinical out-
comes, costs and cost-effectiveness of interventions
in diabetes mellitus (types 1 and 2) to support
clinical and reimbursement decision-making. Curr
Med Res Opin. 2004;20(Suppl 1):S5-26.
19. McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A,
Grant D. Validation of the IMS CORE diabetes
model. Value Health. 2014;17(6):714–24.
20. McCrimmon, Lamotte, Ramos et al. Cost-Effective-
ness of iGlarLixi Versus iDegLira in Type 2 Diabetes
Mellitus Inadequately Controlled by GLP-1 Recep-
tor Agonists and Oral Antihyperglycemic Therapy.
Diabet Ther. 2021, In Press.
21. National Institute for Health and Care Excellence.
Guide to the methods of technology appraisal
2013—Process and methods [PMG9]. 2013. https://
www.nice.org.uk/process/pmg9/chapter/the-
reference-case. Accessed 8 Apr 2021.
22. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The
results of direct and indirect treatment comparisons
3228 Diabetes Ther (2021) 12:3217–3230
in meta-analysis of randomized controlled trials.
J Clin Epidemiol. 1997;50(6):683–91.
23. Pozzilli P, Norwood P, Jodar E, et al. Placebo-con-
trolled, randomized trial of the addition of once-
weekly glucagon-like peptide-1 receptor agonist
dulaglutide to titrated daily insulin glargine in
patients with type 2 diabetes (AWARD-9). Diabetes
Obes Metab. 2017;19(7):1024–31.
24. Ahmann A, Rodbard HW, Rosenstock J, et al. Effi-
cacy and safety of liraglutide versus placebo added
to basal insulin analogues (with or without met-
formin) in patients with type 2 diabetes: a ran-
domized, placebo-controlled trial. Diabetes Obes
Metab. 2015;17(11):1056–64.
25. Clarke PM, Gray AM, Briggs A, et al. A model to
estimate the lifetime health outcomes of patients
with type 2 diabetes: the United Kingdom
Prospective Diabetes Study (UKPDS) Outcomes
Model (UKPDS no. 68). Diabetologia. 2004;47(10):
1747–59.
26. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM.
UKPDS outcomes model 2: a new version of a
model to simulate lifetime health outcomes of
patients with type 2 diabetes mellitus using data
from the 30 year United Kingdom Prospective
Diabetes Study: UKPDS 82. Diabetologia.
2013;56(9):1925–33.
27. Rosenstock J, Guerci B, Hanefeld M, et al. Prandial
options to advance basal insulin glargine therapy:
testing Lixisenatide plus basal insulin versus insulin
glulisine either as basal-plus or basal-bolus in type 2
diabetes: the GetGoal Duo-2 trial. Diabetes Care.
2016;39(8):1318–28.
28. Ramos M, Cummings MH, Ustyugova A, Raza SI, de
Silva SU, Lamotte M. Long-term cost-effectiveness
analyses of empagliflozin versus oral semaglutide,
in addition to metformin, for the treatment of type
2 diabetes in the UK. Diabetes Ther. 2020;11(9):
2041–55.
29. Curtis LA, Burns A. Unit Costs of Health and Social
Care 2020. Canterbury: University of Kent Personal
Social Services Research Unit (PSSRU). https://www.
pssru.ac.uk/project-pages/unit-costs/unit-costs-
2020/. Accessed 8 Apr 2021.
30. York Health Economics Consortium. Net Monetary
Benefit. 2016. https://yhec.co.uk/glossary/net-
monetary-benefit/. Accessed 6 July 2021.
31. Pohlmann J, Montagnoli R, Lastoria G, Parekh W,
Markert M, Hunt B. Value for money in the treat-
ment of patients with type 2 diabetes mellitus:
assessing the long-term cost-effectiveness of IDe-
gLira versus iGlarLixi in Italy. Clinicoecon Out-
comes Res. 2019;11:605–14.
32. Pohlmann J, Russel-Szymczyk M, Holik P, Rychna
K, Hunt B. Treating patients with type 2 diabetes
mellitus uncontrolled on basal insulin in the Czech
Republic: cost-effectiveness of IDegLira versus
iGlarLixi. Diabetes Ther. 2019;10(2):493–508.
33. Evans M, Billings LK, Hakan-Bloch J, et al. An
indirect treatment comparison of the efficacy of
insulin degludec/liraglutide (IDegLira) and insulin
glargine/lixisenatide (iGlarLixi) in patients with
type 2 diabetes uncontrolled on basal insulin. J Med
Econ. 2018;21(4):340–7.
34. National Institute for Healthcare and Excellence.
Type 1 diabetes in adults: diagnosis and manage-
ment—Insulin therapy. NICE guideline NG17—




35. American Diabetes Association. Guidelines for
computer modeling of diabetes and its complica-
tions. Diabetes Care. 2004;27(9):2262–5.
36. Tofe S, Arguelles I, Mena E, et al. Real-world GLP-1
RA therapy in type 2 diabetes: a long-term effec-
tiveness observational study. Endocrinol Diabetes
Metab. 2019;2(1):e00051.
37. Guerci B, Charbonnel B, Gourdy P, et al. Efficacy
and adherence of glucagon-like peptide-1 receptor
agonist treatment in patients with type 2 diabetes
mellitus in real-life settings. Diabetes Metab.
2019;45(6):528–35.
38. Lin J, Lingohr-Smith M, Fan T. Real-world medica-
tion persistence and outcomes associated with basal
insulin and glucagon-like peptide 1 receptor ago-
nist free-dose combination therapy in patients with
type 2 diabetes in the US. Clinicoecon Outcomes
Res. 2017;9:19–29.




sed 30 July 2021.
40. NHS Scotland. Monitoring and evaluating Scot-
land’s alcohol strategy: Monitoring Report 2017.
NHS Health Scotland. 2017. http://www.
healthscotland.scot/media/1449/mesas-final-
report_english1.pdf. Accessed 30 July 2021.
41. Rubino A, Rousculp MD, Davis K, Wang J, Girach A.
Diagnosed diabetic retinopathy in France, Italy,
Spain, and the United Kingdom. Prim Care Dia-
betes. 2007;1(2):75–80.
42. British Medical Association and the Royal Pharma-
ceutical Society. British National Formulary. 2020.
Diabetes Ther (2021) 12:3217–3230 3229
https://about.medicinescomplete.com/help/.
Accessed 31 May 2021.
43. Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan
P. Review of utility values for economic modeling
in type 2 diabetes. Value Health. 2014;17(4):
462–70.
44. Lauridsen JT, Lonborg J, Gundgaard J, Jensen HH.
Diminishing marginal disutility of hypoglycaemic
events: results from a time trade-off survey in five
countries. Qual Life Res. 2014;23(9):2645–50.
45. Foos V, McEwan P. Conversion of hypoglycemia
utility decrements from categorical units reflecting
event history into event specific disutility scores
applicable to diabetes decision models. Value
Health. 2018;21:S223.
46. Bagust A, Beale S. Modelling EuroQol health-related
utility values for diabetic complications from
CODE-2 data. Health Econ. 2005;14(3):217–30.
3230 Diabetes Ther (2021) 12:3217–3230
